Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Preoperative breast imaging review: Interests and limits of specialized validation in oncology].
Flory V, Lévy G, Viotti J, Schiappa R, Elkind L, Ghez C, Pellegrin A, Occelli A, Dejode M, Delpech Y, Fouché Y, Figl A, Machiavello JC, Haudebourg J, Peyrottes I, Chapellier C, Barranger E. Flory V, et al. Among authors: schiappa r. Bull Cancer. 2020 Mar;107(3):295-307. doi: 10.1016/j.bulcan.2019.11.013. Epub 2020 Feb 27. Bull Cancer. 2020. PMID: 32115178 French.
Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: A retrospective bicenter study by the SFRO brachytherapy group.
Ka K, Schiappa R, Terlizzi M, Mallet F, Martin E, Chand ME, Demogeot N, Peiffert D, Pommier P, Quivrin M, Kissel M, Pasquier C, Khalifa J, Bossi A, Hannoun-Levi JM, Blanchard P. Ka K, et al. Among authors: schiappa r. Radiother Oncol. 2023 Mar;180:109460. doi: 10.1016/j.radonc.2022.109460. Epub 2023 Jan 10. Radiother Oncol. 2023. PMID: 36638842
Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial.
Gerard JP, Barbet N, Schiappa R, Magné N, Martel I, Mineur L, Deberne M, Zilli T, Dhadda A, Myint AS; ICONE group. Gerard JP, et al. Among authors: schiappa r. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):356-367. doi: 10.1016/S2468-1253(22)00392-2. Epub 2023 Feb 16. Lancet Gastroenterol Hepatol. 2023. PMID: 36801007 Clinical Trial.
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.
Dufies M, Giuliano S, Viotti J, Borchiellini D, Cooley LS, Ambrosetti D, Guyot M, Ndiaye PD, Parola J, Claren A, Schiappa R, Gal J, Frangeul A, Jacquel A, Cassuto O, Grépin R, Auberger P, Bikfalvi A, Milano G, Escudier B, Rioux-Leclercq N, Porta C, Negrier S, Chamorey E, Ferrero JM, Pagès G. Dufies M, et al. Among authors: schiappa r. Br J Cancer. 2017 Sep 26;117(7):947-953. doi: 10.1038/bjc.2017.276. Epub 2017 Aug 29. Br J Cancer. 2017. PMID: 28850564 Free PMC article. Clinical Trial.
Accelerated partial breast irradiation for suitable elderly women using a single fraction of multicatheter interstitial high-dose-rate brachytherapy: Early results of the Single-Fraction Elderly Breast Irradiation (SiFEBI) Phase I/II trial.
Hannoun-Lévi JM, Cham Kee DL, Gal J, Schiappa R, Hannoun A, Gautier M, Boulahssass R, Peyrottes I, Barranger E, Ferrero JM, Chand ME, Doyen J. Hannoun-Lévi JM, et al. Among authors: schiappa r. Brachytherapy. 2018 Mar-Apr;17(2):407-414. doi: 10.1016/j.brachy.2017.11.008. Epub 2017 Dec 15. Brachytherapy. 2018. PMID: 29254856 Clinical Trial.
Impact of HPV-associated p16-expression and other clinical factors on therapeutic decision-making in patients with oropharyngeal cancer: A GETTEC multicentric study.
Culié D, Garrel R, Viotti J, Schiappa R, Chamorey E, Fakhry N, Lallemant B, Vergez S, Dupret-Bories A, Dassonville O, Poissonnet G, Santini J, Peyrade F, Benezery K, Sudaka A, Jourdan-Soulier F, Chapel F, Guelfucci B, Bozec A. Culié D, et al. Among authors: schiappa r. Eur J Surg Oncol. 2018 Dec;44(12):1908-1913. doi: 10.1016/j.ejso.2018.05.022. Epub 2018 May 25. Eur J Surg Oncol. 2018. PMID: 29871820
DPD status and fluoropyrimidines-based treatment: high activity matters too.
Chamorey E, Francois E, Etienne MC, Ferrero JM, Peyrade F, Barranger E, Bozec A, Largillier R, Cassuto O, Viotti J, Schiappa R, Milano G. Chamorey E, et al. Among authors: schiappa r. BMC Cancer. 2020 May 18;20(1):436. doi: 10.1186/s12885-020-06907-0. BMC Cancer. 2020. PMID: 32423482 Free PMC article.
103 results